El interés en corto de SciSparc da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de SciSparc. Los datos de interés en corto se actualizan cada dos semanas.

SciSparc (NASDAQ:SPRC) Bolsa, Informe de interés en corto

SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.

Equities

Eurozone

Commodities

Intraday Update

Markets

AEON

BHAT

BLRX

FUBO

SPRC

Los mercados financieros avanzan con el Dow Jones subiendo 200 puntos. Conoce las acciones ganadoras, caídas y tendencias en materias primas.

Índices bursátiles al alza: Las acciones tecnológicas impulsan a Wall Street este lunes

SciSparc Ltd

MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) has outperformed the market over the past 5 years by 4.74% on an annualized basis producing an average annual return of 18.79%. Currently, MercadoLibre has a market capitalization of $121.95 billion. 
Buying $100 In MELI: If an investor had bought $100 of MELI stock 5 years ago, it would be worth $235.15 today based on a price of $2405.44 for MELI at the time of writing.
<h3>MercadoLibre's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752769815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

MELI

Here's How Much You Would Have Made Owning MercadoLibre Stock In The Last 5 Years

Editor's note: The article and headline have been corrected to clarify Chamath Palihapitiya's SPAC involvement and update the price performance.
Three SPAC‑listed companies—SoFi Technologies Inc. (NASDAQ: SOFI) and Opendoor Technologies Inc. (NASDAQ: OPEN), both taken public via <a href="https://www.benzinga.com/topic/chamath-palihapitiya">Chamath Palihapitiya</a>–sponsored vehicles, and MP Materials Corp. (NYSE: MP), which merged with Fortress Value Acquisition Corp. in a deal anchored by a PIPE that included Palihapitiya—are staging an unexpected comeback in 2025, posting year‑to‑date returns that outpace even tech giant Nvidia Corp. (NASDAQ: NVDA). <a href="https://mpmaterials.com/news//press-release-11-17-2020/?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener"></a>
<h2 class="wp-block-heading">Surging Stock Performance</h2>
While Nvidia remains a headline grabber with a monthly gain of roughly 20%, Chamath's SPAC trio has quietly delivered impressive returns. Opendoor ($OPEN) leads the pack, rallying around 190% over the past month, followed by MP Materials ($MP) at 65% and SoFi ($SOFI) up about 52%.
This resurgence marks a significant turnaround after years of skepticism surrounding SPACs.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/06/46012786/chamath-palihapitiya-asks-if-he-should-launch-another-spac-70-say-no-users-warn-of-past-failures-no-crying-in-the-casino">Chamath Palihapitiya Asks If He Should Launch Another SPAC—70% Say No, Users Warn of Past Failures: &#8216;No Crying In The Casino!&#8217;</a>
<h2 class="wp-block-heading">Why The Revival?</h2>
These stocks have shaken off their "SPAC stigma" by showing improving fundamentals and strategic pivots. 
<ul class="wp-block-list">
<li>SoFi, initially a fintech darling, has broadened its offerings and grown its user base. </li>
<li>MP Materials, a company specializing in rare-earth materials, benefits from increased demand amid supply chain and geopolitical tensions.</li>
<li>Opendoor, despite some headwinds, has optimized its operations and is riding a recovering real estate market.</li>
</ul>
<h2 class="wp-block-heading">What About $SPCE?</h2>
Investors are now closely watching&nbsp;Virgin Galactic Holdings Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>), the original space-focused SPAC, to see if it can join this rally.
While SPCE&#8217;s 29% gain over the past month pales in comparison to other SPACs, it still manages to outshine Nvidia. The momentum in Chamath's SPACs raises questions about whether a broader "Chamath revival" is underway or if these gains are isolated.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/07/46337678/chamath-palihapitiya-agrees-with-a-social-media-user-who-says-while-meta-spends-200-million-a-year-to-poach-ai-talent-elon-musk-keeps-costs-low-but-still-manages-to-unveil-better-products">Chamath Palihapitiya Agrees With A Social Media User Who Says While Meta Spends $200 Million A Year To Poach AI Talent, Elon Musk Keeps Costs Low But Still Manages To Unveil Better Products</a></li>
</ul>
Photo: Shutterstock

NVDA

OPEN

SOFI

SPCE

Chamath‑Connected SPAC Listings Are Crushing Nvidia — Wall Street Didn't See This Coming (CORRECTED)

WIIM

MDLZ

Mondelez International is trading higher after Jefferies upgraded the stock from hold to buy and raised its price target from $66 to $78.

Shares of auto retail ecosystem companies have outperformed year-to-date, despite the announcement of auto tariffs and industry fundamentals weakening "even before the impact of tariffs have flowed through to vehicle pricing," according to JPMorgan.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e68c15a5f2b9b0001143528/rajat-gupta">Analyst </a><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e68c15a5f2b9b0001143528/rajat-gupta">Rajat Gupta</a> changed ratings on these four stocks.
<h1 class="wp-block-heading">Cars.com</h1>
JPMorgan upgraded the rating for Cars.com Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARS#NYSE">CARS</a>) from Neutral to Overweight, while establishing a price target of $14.
Shares of companies in the business-to-consumer)marketplaces have underperformed franchise dealers so far this year, Gupta said. Although B2C marketplaces are not immune to broader industry pressures, they are better positioned than business-to-business marketplaces, he added.
Cars.com has taken "significant strides in developing new products and solutions that integrate them into dealers' operational workflows, including market intelligence, consumer sourcing functionalities, D2D wholesale, and online retailing, which bodes well for the retention of dealer customers, even amid a volatile industry backdrop," he further wrote.
<h1 class="wp-block-heading">Sonic Automotive</h1>
The analyst downgraded Sonic Automotive Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAH#NYSE">SAH</a>) from Overweight to Underweight, while raising the price target from $65 to $72.
While Sonic Automotive boasts a "strong luxury brand mix and exposure to California and Texas," the company has underperformed its peers, the analyst stated. Its stock currently trades at a premium to peers, "despite macro and industry headwinds and elevated balance sheet leverage," he added. &nbsp;
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
<h1 class="wp-block-heading">Group 1 Automotive</h1>
JPMorgan downgraded Group 1 Automotive Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPI#NYSE">GPI</a>) from Overweight to Neutral, while reducing the price target from $435 to $415.
The company's execution has been solid for several years, "with favorable Texas exposure serving as a relative tailwind," Gupta said. He added, however, that concentration in one state makes for increased volatility, "as regional economic conditions could significantly impact growth."
<h1 class="wp-block-heading">Asbury Automotive Group</h1>
Gupta downgraded Asbury Automotive Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABG#NYSE">ABG</a>) from Neutral to Underweight, while cutting the price target from $235 to $225.
"While Asbury's strategic acquisitions, expansion into captive warranty, and digital investments like Clicklane position it for long-term growth, JPMorgan sees the risk-reward as unfavorable due to integration and execution risks, elevated leverage, and underperformance in used vehicle gross profit since 2019," the analyst wrote.
CARS, SAH, GPI, ABG Price Action: At the time of publication on Thursday,
<ul class="wp-block-list">
<li>Shares of Cars.com had risen by 4.54% to $12.89.</li>
<li>Sonic Automotive's stock had declined by 8.79% to $77.68.</li>
<li>Group 1 Automotive's share price had declined by 7.36% to $411.80.</li>
<li>Shares of Asbury Automotive had declined by 5.72% to $233.98.</li>
</ul>
Read More:<a href="https://www.benzinga.com/markets/equities/25/06/46111337/micron-ceo-cautions-ai-boom-may-not-be-fully-sustainable-flags-tariff-driven-demand-pull-in"> </a> • <a href="https://www.benzinga.com/markets/equities/25/06/46111337/micron-ceo-cautions-ai-boom-may-not-be-fully-sustainable-flags-tariff-driven-demand-pull-in">Inventory Stabilizes, But Cars.com Lags Peers: Analyst Flags Profit Pressures</a>

Photo: Shutterstock

Movers

CARS

Analyst Revs Up Cars.com, Hits The Brakes On 3 Others

CTAS

Cintas is trading higher after the company reported better-than-expected Q4 EPS and sales.

Editor&#8217;s Note: The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous &#8220;outlook cut&#8221; mentioned in the original title.
Swiss pharmaceutical giant Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) reported second-quarter 2025 earnings on Thursday and raised its full-year earnings forecast.
Quarterly sales reached $14.05 billion, almost in line with the analysts&#8217; consensus <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimate of $14.06 billion</a>.
Net sales <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-reports-strong-q2-double-digit-sales-growth-and-core-margin-expansion-raises-fy-2025-core-operating-income-guidance" rel="noreferrer noopener">grew</a> 12% year over year (+11% on constant currency or cc) with core operating income up 20% to $5.93 billion (+21% on constant currency).
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46292859/novartis-gets-swiss-approval-for-first-malaria-drug-for-babies" rel="noreferrer noopener">Novartis Gets Swiss Approval For First Malaria Drug For Babies</a>
Sales growth driven by performance from breast cancer treatment, Kisqali ($1.18 billion, +64% cc), Entresto ($2.36 billion, +22% cc), multiple sclerosis drug, Kesimpta ($1.08 billion, +33% cc), Scemblix ($298 million, +79% cc), Leqvio ($298 million, +61% cc), and Pluvicto ($454 million, +30% cc).
Novartis reported adjusted earnings of $2.42 per share, beating the consensus of $2.38.
The company also announced a substantial share buyback program. Novartis said it is initiating a share buyback of up $10 billion to be completed by year-end 2027.
&#8220;Our robust balance sheet and confidence in our mid- and long-term growth enable us to initiate an up-to $10 billion share buyback as part of our commitment to balanced capital allocation,&#8221; stated CEO Vas Narasimhan in a statement on Thursday.
Earlier in July, Novartis released topline results from the Phase 3 GCAptAIN study evaluating Cosentyx (secukinumab) for newly diagnosed or relapsing <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">giant cell arteritis (GCA)</a>.
The study evaluated Cosentyx with a 26-week steroid taper and compared it to a placebo plus a 52-week steroid taper.&nbsp;Cosentyx did not demonstrate a statistically significant improvement in sustained remission at <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46243947/novartis-cosentyx-fails-late-stage-giant-cell-arteritis-trial" rel="noreferrer noopener">Week 52 compared to placebo</a>.
<h2 class="wp-block-heading">Outlook</h2>
For fiscal year 2025, Novartis reaffirms that net sales will grow in the high single digits. 2025 core operating income is expected to grow in the low teens, compared to the low double <a target="_blank" href="https://www.benzinga.com/25/04/45075714/novartis-q1-earnings-beat-street-view-ceo-confident-to-deliver-upgraded-2025-guidance" rel="noreferrer noopener">digits forecasted earlier</a>.
&#8220;We continue to assume Entresto US generic entry in mid-2025 for forecasting purposes, though the timing of generic entry is subject to ongoing IP and regulatory litigation,&#8221; Novartis said in the release.
<h2 class="wp-block-heading">Management Update</h2>
In a separate announcement, Novartis provided a key leadership update: Chief Financial Officer Harry Kirsch will <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-appoints-mukul-mehta-chief-financial-officer-harry-kirsch-retires-after-22-years-company" rel="noreferrer noopener">retire</a> in March 2026, concluding an impressive 22-year tenure at the company, including 12 years in the CFO role since 2013.
He will be succeeded by Mukul Mehta, who currently serves as the company&#8217;s head of business planning and analysis, digital finance, and tax.
Price Action: NVS stock is trading lower by 1.71% to $116.35 during the premarket session at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46463670/supermicro-launches-new-ai-servers-with-intel-xeon-6-chips" target="_blank" rel="noreferrer noopener">Supermicro Launches New AI Servers With Intel Xeon 6 Chips</a></li>
</ul>
Photo via Shutterstock

Biotech

Earnings

Large Cap

Guidance

Health Care

Buybacks

Management

General

Novartis Raises Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback (CORRECTED)

Unity Software shares are trading higher after UBS raised its price target on the stock from $22 to $33. Also, Wedbush raised its price target on the stock from $31.5 to $39.

The Trade Desk shares are trading higher after multiple analysts raised their price targets on the stock.

Primerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) has outperformed the market over the past 10 years by 8.02% on an annualized basis producing an average annual return of 19.51%. Currently, Primerica has a market capitalization of $8.63 billion. 
Buying $1000 In PRI: If an investor had bought $1000 of PRI stock 10 years ago, it would be worth $5,885.71 today based on a price of $262.59 for PRI at the time of writing.
<h3>Primerica's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752768911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Primerica 10 Years Ago Would Be Worth Today

Webull Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>) shares are trading higher Thursday after the company announced it will reintroduce crypto trading to its global customer base and integrate Webull Pay back <a href="https://www.benzinga.com/node/46465772">into Webull Group.</a>
What To Know: Webull said it will consolidate Webull Pay into the broader Webull Group as part of a business combination approved by both companies&#8217; boards and shareholders. The move positions Webull to roll out crypto trading in the United States through its app in the third quarter.
The company cited improved regulatory clarity as a key driver of its decision and said crypto trading is already live in Brazil, with more market expansions planned later this year.
How To Buy Webull Stock
By now you're likely curious about how to participate in the market for Webull (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>) &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Webull, which is trading at $13.70 as of publishing time, $100 would buy you 7.3 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
See Also: <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46466501/interactive-brokers-earnings-are-imminent-these-most-accurate-analysts-revise-">Interactive Brokers Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>
BULL Price Action: At the time of publication, Webull stock is trading 6.2% higher at $13.70, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Image via Shutterstock

BULL

Webull Stock Is Trading Higher Thursday: What's Going On?

Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock is trading higher on Thursday after the company issued an after-hours update on ongoing label expansion efforts for Elevidys, its approved gene therapy <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">for Duchenne muscular dystrophy</a>.
The U.S Food and Drug Administration (FDA) has requested that the label include a black box warning for acute liver injury (ALI) and acute liver failure (ALF).
Sarepta agrees with this change, which appears to resolve any material issues with the ambulant portion of the Elevidys label. In June, Sarepta temporarily suspended shipments of Elevidys for <a href="https://www.benzinga.com/news/fda/25/06/45945282/sarepta-therapeutics-stock-plummets-over-40-on-second-fatal-case-linked-to-its-gene-therapy" target="_blank" rel="noreferrer noopener">non-ambulatory patients</a>.
Also Read: <a href="https://www.benzinga.com/news/fda/25/06/46101643/did-the-fda-make-a-mistake-sareptas-elevidys-approval-under-scrutiny" target="_blank" rel="noreferrer noopener">Did The FDA Make A Mistake? Sarepta&#8217;s Elevidys Approval Under Scrutiny</a>
A Sarepta committee is reviewing cases of ALF and exploring additional <a href="https://www.benzinga.com/pressreleases/25/07/b46454162/sarepta-therapeutics-announces-strategic-restructuring-and-pipeline-prioritization-plan-to-maintai" target="_blank" rel="noreferrer noopener">immunosuppression regimens</a>. The committee agreed on an enhanced immunosuppressive regimen with sirolimus for Elevidys in non-ambulant patients.
Sarepta will submit the expert panel&#8217;s findings and proposed protocol to the FDA and will discuss a proposal to gather data on the regimen in a new cohort (Cohort 8) of the ENDEAVOR study (Study SRP-9001-103) as a pathway to re-establish dosing in the non-ambulant setting.
Additionally, Sarepta is assessing real-world data generation opportunities for ambulant patients through investigator-initiated trials.
<h2 class="wp-block-heading">Strategic Restructuring</h2>
The company announced a strategic restructuring plan to prioritize programs, meet its 2027 financial obligations, and support its long-term financial viability.
The measures are projected to deliver approximately $400 million in annual cost reductions, significantly lowering the company&#8217;s average annual non-GAAP R&amp;D and SG&amp;A expenses to between $800 million and $900 million starting in 2026. These include:
A 36% workforce reduction, impacting approximately 500 employees, projected to generate approximately $120 million in annual cash cost savings in 2026
Pipeline reprioritization is expected to deliver approximately $300 million in annual non-personnel cost savings starting in 2026
Over $100 million in cost savings anticipated through the end of 2025, net of estimated severance and one-time charges totaling $32-$37 million
<h2 class="wp-block-heading">Preliminary Second Quarter 2025 Financial Highlights</h2>
Total net product revenue of $513 million, with Elevidys revenue of $282 million. RNA-based PMOs net product revenue of $231 million.
Cash, cash equivalents, restricted cash, and investments of approximately $850 million as of June 30.
Sarepta will continue to support its four on-market Duchenne therapies and all associated clinical trial activities.
The strategic pivot emphasizes chronically administered therapies for neurodegenerative and pulmonary diseases.
This reprioritization will result in the pause of several programs, including most of the gene therapies in development for limb-girdle muscular dystrophy (LGMD).
Sarepta expects to submit the Biologics License Application for SRP-9003 for LGMD type 2E/R4 later this year.
Sarepta intends to seek strategic alternatives, including partnering, for programs that it no longer intends to fund directly.
<h2 class="wp-block-heading">Management Update</h2>
In conjunction with the restructuring, Sarepta named Ian Estepan President and Chief Operating Officer and Ryan Wong CFO.
<h2 class="wp-block-heading">Analyst Take</h2>
William Blair writes that the FDA&#8217;s request for a black box warning suggests that complete removal of Elevidys from the market is highly unlikely.
&#8220;&#8230;we believe investors have increased confidence that the company can pay off its long-term debts&#8230;,&#8221; analyst Sami Corwin wrote on Thursday.
William Blair expects Elevidys to face short-term challenges as patients and doctors are showing more hesitation.
The analyst also notes that investors are likely to remain cautious about Elevidys's long-term potential until early results from the ENDEAVOR trial demonstrate that the updated immunosuppression approach is effective and sales resume among patients who can still walk.
William Blair reiterates the Market Perform rating.
Price Action: SRPT stock is up 15.9% at $21.30 at the last check on Thursday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46464911/delta-air-lines-to-pay-8-1-million-to-settle-doj-probe-over-alleged-misuse-of-pandemic-relief-funds" target="_blank" rel="noreferrer noopener">Delta Air Lines To Pay $8.1 Million To Settle DOJ Probe Over Alleged Misuse Of Pandemic Relief Funds</a></li>
</ul>
Image: Shutterstock

Analyst Color

Analyst Ratings

SRPT

Sarepta Therapeutics' Reorganization Boosts Investor Confidence

Needham analyst Serge Belanger downgrades Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) from Buy to Hold and announces $3 price target.

Downgrades

Price Target

CLSD

Needham Downgrades Clearside Biomedical to Hold, Announces $3 Price Target

DUBAI, United Arab Emirates, July 17, 2025 (GLOBE NEWSWIRE) -- SEGG Media Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEGG#NASDAQ">SEGG</a>, LTRYW))) ("SEGG Media" or the "Company"), a leading technology company transforming the global intersection of sports, entertainment and gaming today announced its first official football league partnership in the Indian subcontinent through a five-year commercial agreement with the Super League Kerala ("SLK"), valued at more than $11.6 million.
The signing ceremony took place today at the offices of Nook Holdings in One JLT, Dubai, marking the first live football rights acquisition for the Company's flagship Sports.com super app.
The agreement establishes SEGG Media and Sports.com as the exclusive global commercial and broadcast partner for SLK, encompassing:
<ul>
<li>Exclusive international streaming rights across all territories;</li>
<li>Integrated gaming and fan engagement products;</li>
<li>Global sponsorship and brand activation rights; and</li>
<li>Distribution focus across the Indian subcontinent and MENA, especially targeting the vast Keralite diaspora in the Middle East, North America, and Europe</li>
</ul>
Season 1 of the Super League Kerala drew nearly 13 million viewers, with Season 2 aiming for a 25% increase in audience reach through Sports.com's streaming platform and targeted media activation strategy. The Company plans to monetize the deal through a combination of subscription, advertising, and licensing revenue, with rollout beginning immediately ahead of the upcoming season.
"This is more than a sports rights deal — it's a powerful validation of the Sports.com strategy," said Matthew McGahan, CEO and President of SEGG Media. "To enter the Indian market through Kerala — a state with an electrifying football culture and millions of global fans — gives us a high-growth, cash-yielding product to launch the Sports.com super app with force."
Attending today's ceremonial signing at Nook One JLT in Dubai were:
<ul>
<li>Matthew McGahan, CEO &amp; President of SEGG Media</li>
<li>Marc Bircham, Director of SEGG Media and Head of Acquisitions at Sports.com, a division of SEGG Media</li>
<li>Tim Scoffham, CEO of Sports.com Media and Lottery.com International</li>
<li>Mathew Joseph, Director &amp; CEO, Super League Kerala</li>
<li>Firoz Meeran, Director, Super League Kerala</li>
<li>Paul Roy, CEO of GXR</li>
</ul>
"Today marks a milestone," said Marc Bircham. "It's the first of many league partnerships that will power Sports.com across India, Asia, and MENA. We're proud to partner with such a progressive and fast-growing league in SLK."
"We've built Sports.com to become the global home of sport, and this is the first piece of live IP that starts to prove it," added Tim Scoffham. "India is an important territory for us, and this is just the beginning."
"With Sports.com, SLK is now moving to a next-generation fan platform that combines cutting-edge gaming and fan engagement with world-class streaming," said Mathew Joseph, Director &amp; CEO of Super League Kerala.
"From Kerala to the world — this historic partnership makes SLK a truly global property," added Firoz Meeran, Director of Super League Kerala.
The partnership will allow SEGG Media to deliver a tiered subscription model through the Sports.com super app, enabling fans to engage with SLK matches in multiple languages, backed by real-time stats, fantasy integration, and on-demand replays. The deal also includes commercial inventory for local and global sponsors, creating a scalable advertising engine tied to viewership growth.
About Super League Kerala (SLK)

SEGG

SEGG Media Announces Its First Official Football League Partnership In The Indian Subcontinent Through A Five-Year Commercial Agreement With The Super League Kerala, Valued At More Than $11.6M

U.S. Agriculture Secretary Brooke Rollins said that automation and tapping into the Medicaid population are key to replacing migrant farmworkers, as the Trump administration continues its mass deportation efforts.
<h2 class="wp-block-heading">No Amnesty, Strategic Deportations</h2>
&#8220;The president has been unequivocal that there will be no amnesty, and I think that&#8217;s very, very important,&#8221; Rollins told reporters during a July 8 press <a href="https://www.c-span.org/program/news-conference/protecting-us-agriculture-against-foreign-threats/662188">conference</a>. &#8220;We must be strategic in how we are implementing the <a href="https://www.benzinga.com/news/politics/25/06/45943800/trump-orders-ice-to-launch-the-single-largest-mass-deportation-program-in-history-targeting-los-angeles-chicago-and-new-york">mass deportation</a> so as not to compromise our food supply.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – Many are rushing to grab <a href="https://www.benzinga.com/money/mode-mobile-2">4,000 of its pre-IPO shares for just $0.30/share</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
Rollins appeared alongside Republican governors Sarah Huckabee Sanders of Arkansas and Bill Lee of Tennessee to announce the USDA National Farm Security Action Plan. The plan aims to block foreign threats, especially from China, <a href="https://www.benzinga.com/real-estate/25/07/46340278/i-would-disappear-politician-who-fled-communist-china-says-they-want-me-to-shut-up-about-chinas-soft-power-invasion-of-u-s-water-farml">protect U.S. farmland</a>, secure the national food supply and safeguard agricultural research.
She also addressed concerns over foreign ownership of farmland in states like California, saying the issue crosses party lines.
&#8220;Even the Democrat governors and even the blue states realize what a massive threat this is to national security,&#8221; Rollins said. &#8220;We plan to work with everyone no matter which side of the aisle they are from to ensure that the people of this country and our agricultural farmland is protected.&#8221;
Trending: Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a>
<h2 class="wp-block-heading">Workforce Shift Ahead</h2>
Rollins said the president's long-term vision is a "100% American workforce," and that automation and Medicaid work requirements will help make that possible.
"There are 34 million able-bodied adults in our Medicaid program," she said. "There are plenty of workers in America. We just have to make sure we&#8217;re not compromising today."
President Trump&#8217;s recently signed tax and spending bill includes the first federally mandated work requirements for Medicaid recipients. Those rules are set to roll out by the end of 2026.
See Also: This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — <a href="https://www.benzinga.com/money/finally-a-fully-automated-trading-platform-for-individual-investors?">You Can Become an Investor for Just $500.25</a>
Rollins emphasized that while deportations would continue, they would be handled in a way that doesn&#8217;t harm the agriculture sector. &#8220;Ultimately, the answer on this is automation, also some reform within the current governing structure,&#8221; she said.
Trump recently hinted at limited flexibility for farmers. "The farmer knows he&#8217;s not going to hire a murderer," he told <a href="https://www.foxnews.com/politics/trump-urges-temporary-pass-from-immigration-crackdown-key-industries-i-cherish-our-farmers">Fox News</a> end of June, suggesting farmers could help determine who is eligible to stay. "And when we go into a farm and we take away people that have been working there for 15 and 20 years, who were good, who possibly came in incorrectly. And what we're going to do is we're going to do something for farmers where we can let the farmer sort of be in charge."
Read Next: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>
Image: Shutterstock

Agriculture Secretary Brooke Rollins Says Robots, Medicaid Recipients To Replace Migrant Workers

Financial giants have made a conspicuous bearish move on UnitedHealth Group. Our analysis of options history for UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) revealed 50 unusual trades.
Delving into the details, we found 36% of traders were bullish, while 54% showed bearish tendencies. Out of all the trades we spotted, 15 were puts, with a value of $950,832, and 35 were calls, valued at $3,177,036.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $150.0 to $460.0 for UnitedHealth Group during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of UnitedHealth Group stands at 3299.68, with a total volume reaching 15,535.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in UnitedHealth Group, situated within the strike price corridor from $150.0 to $460.0, throughout the last 30 days.
<h3>UnitedHealth Group Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752768078_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/17/27</td>
<td>$113.6</td>
<td>$109.7</td>
<td>$113.6</td>
<td>$210.00</td>
<td>$851.9K</td>
<td>59</td>
<td>135</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.7</td>
<td>$8.6</td>
<td>$8.6</td>
<td>$400.00</td>
<td>$559.0K</td>
<td>13.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/17/27</td>
<td>$108.65</td>
<td>$108.6</td>
<td>$108.6</td>
<td>$210.00</td>
<td>$543.0K</td>
<td>59</td>
<td>60</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$34.35</td>
<td>$31.15</td>
<td>$32.8</td>
<td>$250.00</td>
<td>$459.2K</td>
<td>807</td>
<td>141</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$16.8</td>
<td>$16.7</td>
<td>$16.8</td>
<td>$300.00</td>
<td>$92.4K</td>
<td>6.9K</td>
<td>388</td>
</tr>
</tbody>
</table>

<h3>About UnitedHealth Group</h3>
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
After a thorough review of the options trading surrounding UnitedHealth Group, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>UnitedHealth Group's Current Market Status</h3>
<ul>
<li>Trading volume stands at 7,244,700, with UNH's price down by -1.04%, positioned at $289.44.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 12 days.</li>
</ul>
<h3>Expert Opinions on UnitedHealth Group</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $371.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on UnitedHealth Group with a target price of $337. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on UnitedHealth Group with a target price of $385. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on UnitedHealth Group, maintaining a target price of $418. 
&#x2A; An analyst from Truist Securities persists with their Buy rating on UnitedHealth Group, maintaining a target price of $345. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for UnitedHealth Group with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

UnitedHealth Group Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Ouster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NASDAQ">OUST</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with OUST, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 13 uncommon options trades for Ouster.
This isn't normal.
The overall sentiment of these big-money traders is split between 30% bullish and 15%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $95,150, and 10 are calls, for a total amount of $409,161.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $42.0 for Ouster, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Ouster's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Ouster's substantial trades, within a strike price spectrum from $20.0 to $42.0 over the preceding 30 days.
<h3>Ouster Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752768072_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OUST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$6.0</td>
<td>$5.7</td>
<td>$5.9</td>
<td>$39.00</td>
<td>$67.2K</td>
<td>50</td>
<td align="right">115</td>
</tr>
<tr>
<td>OUST</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/01/25</td>
<td>$2.0</td>
<td>$1.5</td>
<td>$1.75</td>
<td>$33.00</td>
<td>$53.2K</td>
<td>74</td>
<td align="right">505</td>
</tr>
<tr>
<td>OUST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$5.0</td>
<td>$4.7</td>
<td>$4.7</td>
<td>$29.00</td>
<td>$47.2K</td>
<td>1.9K</td>
<td align="right">123</td>
</tr>
<tr>
<td>OUST</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$13.0</td>
<td>$12.0</td>
<td>$12.5</td>
<td>$35.00</td>
<td>$41.2K</td>
<td>15</td>
<td align="right">51</td>
</tr>
<tr>
<td>OUST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/01/25</td>
<td>$1.0</td>
<td>$0.95</td>
<td>$1.0</td>
<td>$36.00</td>
<td>$38.6K</td>
<td>0</td>
<td align="right">386</td>
</tr>
</tbody>
</table>

<h3>About Ouster</h3>
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
After a thorough review of the options trading surrounding Ouster, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Ouster</h3>
<ul>
<li>Currently trading with a volume of 1,710,592, the OUST's price is up by 1.1%, now at $29.35. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 21 days.</li>
</ul>
<h3>Professional Analyst Ratings for Ouster</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $34.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Ouster, which currently sits at a price target of $34. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Ouster with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

OUST

A Closer Look at Ouster's Options Market Dynamics

Whales with a lot of money to spend have taken a noticeably bullish stance on Centrus Energy.
Looking at options history for Centrus Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LEU#AMEX">LEU</a>) we detected 26 trades.
If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish expectations and 38% with bearish.
From the overall spotted trades, 13 are puts, for a total amount of $719,220 and 13, calls, for a total amount of $669,381.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $90.0 and $300.0 for Centrus Energy, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Centrus Energy stands at 189.85, with a total volume reaching 919.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Centrus Energy, situated within the strike price corridor from $90.0 to $300.0, throughout the last 30 days.
<h3>Centrus Energy Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752768067_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LEU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$5.1</td>
<td>$3.6</td>
<td>$4.1</td>
<td>$230.00</td>
<td>$135.2K</td>
<td align="right">56</td>
<td align="right">343</td>
</tr>
<tr>
<td>LEU</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/21/25</td>
<td>$98.3</td>
<td>$95.5</td>
<td>$96.92</td>
<td>$150.00</td>
<td>$96.9K</td>
<td align="right">233</td>
<td align="right">40</td>
</tr>
<tr>
<td>LEU</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$31.0</td>
<td>$29.9</td>
<td>$30.4</td>
<td>$240.00</td>
<td>$94.2K</td>
<td align="right">6</td>
<td align="right">59</td>
</tr>
<tr>
<td>LEU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$96.0</td>
<td>$93.2</td>
<td>$94.2</td>
<td>$150.00</td>
<td>$94.2K</td>
<td align="right">233</td>
<td align="right">20</td>
</tr>
<tr>
<td>LEU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$94.2</td>
<td>$93.2</td>
<td>$94.2</td>
<td>$150.00</td>
<td>$94.2K</td>
<td align="right">233</td>
<td align="right">10</td>
</tr>
</tbody>
</table>

<h3>About Centrus Energy</h3>
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
After a thorough review of the options trading surrounding Centrus Energy, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Centrus Energy</h3>
<ul>
<li>Currently trading with a volume of 481,406, the LEU's price is up by 1.19%, now at $229.97. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 19 days.</li>
</ul>
<h3>What The Experts Say On Centrus Energy</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $199.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Evercore ISI Group persists with their Outperform rating on Centrus Energy, maintaining a target price of $205. 
&#x2A; An analyst from Stifel downgraded its action to Buy with a price target of $220. 
&#x2A; Reflecting concerns, an analyst from Northland Capital Markets lowers its rating to Outperform with a new price target of $205. 
&#x2A; An analyst from B. Riley Securities persists with their Buy rating on Centrus Energy, maintaining a target price of $221. 
&#x2A; An analyst from JP Morgan has revised its rating downward to Neutral, adjusting the price target to $148. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Centrus Energy, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Centrus Energy Options Trading: A Deep Dive into Market Sentiment

Corcept Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NYSE">CORT</a>) short percent of float has fallen 9.51% since its last report. The company recently reported that it has 11.45 million shares sold short, which is 14.55% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.6 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Corcept Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752768037_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Corcept Therapeutics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Corcept Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Corcept Therapeutics's peer group average for short interest as a percentage of float is 2.89%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

CORT

What's Driving the Market Sentiment Around Corcept Therapeutics?

Shares of Coinbase Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) are surging to a new all-time high on Thursday, bolstered by a bullish analyst revision and positive legislative momentum. Here&#8217;s what investors <a href="https://www.benzinga.com/quote/COIN/news">need to know</a>.
What To Know: Rosenblatt analyst Chris Brendler reiterated a Buy rating on the stock while significantly raising his price target to $470 from $300, reflecting growing confidence in the company&#8217;s market position.
This record performance builds on <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46448405/why-coinbase-global-stock-hit-a-new-52-week-high-today">Wednesday&#8217;s momentum</a>, which was fueled by a dramatic legislative turnaround in Washington. Key crypto bills, including the GENIUS Act for stablecoins and the CLARITY Act for market structure, were revived after President Donald Trump announced he had secured the necessary Republican votes to advance them. The sudden reversal reignited optimism for U.S. crypto regulation after the bills had initially stalled in the House.
The renewed legislative push is a major bullish catalyst, promising regulatory clarity. The GENIUS Act is particularly crucial for Coinbase, as it would establish a U.S. framework for major stablecoins like Circle's $USDC a foundational asset for the exchange&#8217;s ecosystem.
Investors are likely viewing the potential for <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46448405/why-coinbase-global-stock-hit-a-new-52-week-high-today">clear regulations</a> as a significant de-risking event for the industry, fueling confidence in platforms like Coinbase.
Benzinga Edge Rankings: According to <a href="http://benzinga.grsm.io/register174">Benzinga Edge</a> data, which uses four critical scores to rank stocks, Coinbase shows a mixed but compelling profile. The company exhibits exceptionally high Momentum with a score of 92.22 and strong Growth at 85.49, reflecting its powerful price appreciation and expanding business operations. 
Conversely, the stock scores very poorly on Value, with a rating of just 15.45. This indicates that while the stock is performing strongly, it is considered expensive relative to its underlying financial metrics. This data paints a picture of a classic high-flying growth stock whose price performance has significantly outpaced its traditional valuation.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, COIN shares are trading higher by 2.2% to $407.05 Thursday morning. The stock has a 52-week high of $415.96 and a 52-week low of $142.58.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46448405/why-coinbase-global-stock-hit-a-new-52-week-high-today">Why Coinbase Global Stock Hit A New 52-Week High Today</a>
<h2 class="wp-block-heading">How To Buy COIN Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Coinbase Global&#8217;s case, it is in the Financials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

COIN

Coinbase Global Stock Hit A New 52-Week High Today: What's Going On?

Ollie's Bargain Outlet's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NYSE">OLLI</a>) short percent of float has risen 3.99% since its last report. The company recently reported that it has 3.92 million shares sold short, which is 7.56% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.83 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Ollie's Bargain Outlet Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752768032_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ollie's Bargain Outlet has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ollie's Bargain Outlet's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Ollie's Bargain Outlet's peer group average for short interest as a percentage of float is 10.66%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

OLLI

Is the Market Bullish or Bearish on Ollie's Bargain Outlet?

Press Releases

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

Contracts

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

Legal

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

Bulls Turn to Pennies STSS, ADTX, CSDX, SPRC, CBDW, YGTFF During Market Uncertainty – Small-Cap Stocks Poised for Big Moves

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

Comments

SciSparc

Interés en corto

SciSparc (NASDAQ:SPRC) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL